Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.01% of ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Teva Pharmaceutical Industries Ltd. ADR 26.47% $18.82B ...

Deutsche Bank has recently reduced GSK plc (GSK) stock to Hold rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 12, 2024, Jefferies had reduced the stock from a Buy ...

Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for GSK in a research report issued ...

GSK GSK stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the ...